Patents by Inventor Toshio Nishihara
Toshio Nishihara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11759509Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.Type: GrantFiled: October 17, 2018Date of Patent: September 19, 2023Assignees: Sumitomo Pharma Co., Ltd., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.Inventors: Chiang Jia Li, Hitoshi Ban, Yukihiro Nishio, Masashi Goto, Toshio Nishihara, Yosuke Takanashi
-
Publication number: 20190030149Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.Type: ApplicationFiled: October 17, 2018Publication date: January 31, 2019Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.Inventors: Chiang Jia LI, Hitoshi Ban, Yukihiro Nishio, Masashi Goto, Toshio Nishihara, Yosuke Takanashi
-
Patent number: 9765114Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.Type: GrantFiled: February 26, 2016Date of Patent: September 19, 2017Assignees: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Toshio Nishihara, Masashi Gotoh
-
Publication number: 20160168197Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.Type: ApplicationFiled: February 26, 2016Publication date: June 16, 2016Applicants: International Institute of Cancer Immunology, Inc., Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd.Inventors: Toshio NISHIHARA, Masashi Gotoh
-
Publication number: 20160114019Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.Type: ApplicationFiled: December 30, 2015Publication date: April 28, 2016Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.Inventors: Chiang Jia Li, Hitoshi Ban, Yukihiro Nishio, Masashi Goto, Toshio Nishihara, Yosuke Takanashi
-
Patent number: 9273148Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.Type: GrantFiled: September 10, 2013Date of Patent: March 1, 2016Assignees: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., CHUGAI SEIYAKU KABUSHIKI KAISHA, SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Toshio Nishihara, Masashi Gotoh
-
Patent number: 9248173Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.Type: GrantFiled: May 7, 2015Date of Patent: February 2, 2016Assignees: SUMITOMO DAINIPPON PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.Inventors: Chiang Jia Li, Hitoshi Ban, Yukihiro Nishio, Masashi Goto, Toshio Nishihara, Yosuke Takanashi
-
Patent number: 9181302Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.Type: GrantFiled: November 20, 2014Date of Patent: November 10, 2015Assignees: SUMITOMO DAINIPPON PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.Inventors: Chiang Jia Li, Hitoshi Ban, Yukihiro Nishio, Masashi Goto, Toshio Nishihara, Yosuke Takanashi
-
Publication number: 20150238587Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.Type: ApplicationFiled: May 7, 2015Publication date: August 27, 2015Applicants: Sumitomo Dainippon Pharma Co., Ltd., International Institute of Cancer Immunology, Inc.Inventors: Chiang Jia LI, Hitoshi Ban, Yukihiro Nishio, Masashi Goto, Toshio Nishihara, Yosuke Takanashi
-
Publication number: 20140046036Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.Type: ApplicationFiled: September 10, 2013Publication date: February 13, 2014Applicants: International Institute of Cancer Immunology, Inc., Dainippon Sumitomo Pharma Co., Ltd., Chugai Seiyaku Kabushiki KaishaInventors: Toshio NISHIHARA, Masashi Gotoh
-
Patent number: 8575308Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.Type: GrantFiled: March 22, 2011Date of Patent: November 5, 2013Assignees: International Institute of Cancer Immunology, Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd.Inventors: Toshio Nishihara, Masashi Gotoh
-
Publication number: 20110229506Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.Type: ApplicationFiled: March 22, 2011Publication date: September 22, 2011Applicants: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., CHUGAI SEIYAKU KABUSHIKI KAISHA, DAINIPPON SUMITOMO PHARMA CO., LTD.Inventors: TOSHIO NISHIHARA, MASASHI GOTOH
-
Patent number: 7939627Abstract: A compound of formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond; R1 is a hydrogen atom; R2 is a hydroxy group; R3 is a hydrogen atom, alkyl group, amino group substituted alkylcarbonylamino; R4 is a hydrogen atom, alkyl group, carboxy group a group of formula (2): wherein W is an amino acid residue; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.Type: GrantFiled: November 29, 2006Date of Patent: May 10, 2011Assignees: International Institute of Cancer Immunology, Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd.Inventors: Toshio Nishihara, Masashi Gotoh
-
Publication number: 20100062010Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.Type: ApplicationFiled: November 29, 2006Publication date: March 11, 2010Applicants: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., CHUGAI SEIYAKU KABUSHIKI KAISHA, DAINIPPON SUMITOMO PHARMA CO., LTD.Inventors: Toshio Nishihara, Masashi Gotoh
-
Patent number: 6936736Abstract: A compound of the formula: wherein Ar is optionally substituted phenyl, etc.; n is 0, 1 or 2; R1 is hydogen atom, optionally substituted alkyl, etc.; R2 and R3 are independently optionally substituted alkyl, etc.; R4 and R5 are independently hydrogen atom or optionally substituted alkyl; R6 is hydrogen atom, hydroxy or alkyl; or a pharmaceutically acceptable salt thereof is useful as a medicament for treating retinal degenerative disorders and the like.Type: GrantFiled: March 26, 2002Date of Patent: August 30, 2005Assignee: Sumitomo Manufacturing Company LimitedInventors: Kazuhito Ikeda, Tohru Tatsuno, Hiroki Ogo, Toshio Nishihara, Tatsuya Fujibayashi, Ryu Nagata
-
Publication number: 20020147204Abstract: A compound of the formula: 1Type: ApplicationFiled: March 26, 2002Publication date: October 10, 2002Applicant: Sumitomo Pharmaceuticals Company, LimitedInventors: Kazuhito Ikeda, Tohru Tatsuno, Hiroki Ogo, Toshio Nishihara, Tatsuya Fujibayashi, Ryu Nagata
-
Patent number: 6384033Abstract: A compound of the formula: wherein Ar is optionally substituted phenyl, etc.; n is 0, 1 or 2; R1 is hydogen atom, optionally substituted alkyl, etc.; R2 and R3 are independently optionally substituted alkyl, etc.; R4 and R5 are independently hydrogen atom or optionally substituted alkyl; R6 is hydrogen atom, hydroxy or alkyl; or a pharmaceutically acceptable salt thereof is useful as a medicament for treating retinal degenerative disorders and the like.Type: GrantFiled: April 27, 2000Date of Patent: May 7, 2002Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Kazuhito Ikeda, Tohru Tatsuno, Hiroki Ogo, Toshio Nishihara, Tatsuya Fujibayashi, Ryu Nagata
-
Patent number: 6293080Abstract: A sewing thread for a leather product composed of fibers attached with a highly water absorbing powdery material on the surface of the fibers, in a ratio of 5 weight % or more based on the weight of the fibers, and a leather product, with excellent water-proof property, prepared by using the same thread.Type: GrantFiled: December 22, 1998Date of Patent: September 25, 2001Assignee: Teijin LimitedInventors: Toshio Nishihara, Tuyoshi Torikai
-
Patent number: 6048854Abstract: The present invention relates to a 2,3-diaminopropionic acid derivative of the formula (1): ##STR1## or a pharmaceutically acceptable salt thereof. The compounds of the present invention are useful as a platelet aggregation inhibitor, a cancer metastasis inhibitor, a wound healing agent or a bone resorption inhibitor.Type: GrantFiled: September 25, 1997Date of Patent: April 11, 2000Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Yoshiharu Ikeda, Yasuyuki Ueki, Hisakazu Kishimoto, Toshio Nishihara, Yumiko Kamikawa
-
Patent number: 5759991Abstract: The invention provides human- or rat-derived neurotrophic peptides and derivatives thereof, precursor peptides thereof, genes encoding the same, transformants containing recombinant expression vectors bearing the genes, and compositions comprising as an effective ingredient these neurotrophic peptides or derivatives thereof. The neurotrophic peptide or its derivatives of the present invention have a neurotrophic activity and are useful for the treatment of neuro-degenerative disorders and dementia.Type: GrantFiled: February 27, 1995Date of Patent: June 2, 1998Assignees: Sumitomo Pharmaceutical Company, Limited., Kosei Ojika, Masahiko YamamotoInventors: Naoki Tohdoh, Shin-ichiro Tojo, Shin-ichi Kojima, Yasuyuki Ueki, Toshio Nishihara, Nobuyuki Fukushima, Tsunemasa Irie, Keiichi Ono, Hideo Agui, Kosei Ojika